Home/Pipeline/Bispecific Antibody Programs

Bispecific Antibody Programs

Undisclosed cancers

PreclinicalEarly-stage

Key Facts

Indication

Undisclosed cancers

Phase

Preclinical

Status

Early-stage

Company

Compugen

About Compugen

Compugen is transforming the pathway to immuno-oncology therapeutics through its unique 'From Code to Cure®' approach. Its flexible-loop Unigen™ platform integrates AI/ML innovation with biological data to discover novel targets and develop first-in-class drugs for cancer patients refractory to current treatments. The company has validated its platform through multiple partnerships with pharmaceutical companies and is advancing a pipeline of clinical-stage programs targeting novel pathways in immuno-oncology.

View full company profile

Therapeutic Areas

Oncology Immuno-oncology

Other Undisclosed cancers Drugs

Drug	Company	Phase	Status
Next-generation ADCs	Sutro Biopharma	Discovery/Preclinical	Active
Cytokine-based Immuno-oncology	Sutro Biopharma	Research	Active